Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): A randomised control trial

  • Colin A Hutchison1, 2Email author,
  • Mark Cook3,
  • Nils Heyne4,
  • Katja Weisel5,
  • Lucinda Billingham6,
  • Arthur Bradwell7 and
  • Paul Cockwell1, 2
Trials20089:55

https://doi.org/10.1186/1745-6215-9-55

Received: 01 July 2008

Accepted: 28 September 2008

Published: 28 September 2008

Abstract

Background

Renal failure is a frequent complication of multiple myeloma and when severe is associated with a greatly increased morbidity and mortality. The principal cause of severe renal failure is cast nephropathy, a direct consequence of high concentrations of monoclonal free light chains (FLCs) in patients' sera. FLC removal by extended haemodialysis, using a high cut-off dialyser, has recently been described as a novel therapeutic option.

Methods

The EU ropean trial of free LI ght chain removal by exTE nded haemodialysis in cast nephropathy (EuLITE) trial is a prospective, randomised, multicentre, open label clinical trial to investigate the clinical benefits of FLC removal haemodialysis in patients with cast nephropathy, dialysis dependent acute renal failure and de novo multiple myeloma. Recruitment commenced in May 2008. In total, 90 patients will be recruited. Participants will be randomised, centrally, upon enrolment, to either trial chemotherapy and FLC removal haemodialysis or trial chemotherapy and standard high flux haemodialysis. Trial chemotherapy consists of bortezomib, doxorubicin and dexamethasone. FLC removal haemodialysis is undertaken with two Gambro HCO 1100 dialysers in series using an intensive treatment schedule. The primary outcome for the study is independence of dialysis at 3 months. Secondary outcomes are: duration of dialysis, reduction in serum FLC concentrations; myeloma response and survival.

Hypothesis

FLC removal haemodialysis will increase the rate of renal recovery in patients with severe renal failure secondary to cast nephropathy in de novo multiple myeloma.

Trial registration

ISRCTN45967602

Background

Renal impairment is a frequent complication of multiple myeloma affecting between 18 and 56% of patients at presentation [14]. When severe it is associated with a greatly increased morbidity and mortality. However, improvement of renal function also improves the patients' survival [2, 5, 6]. Previous studies have demonstrated that the principal cause of severe renal failure in patients with multiple myeloma is cast nephropathy, a direct consequence of the high concentrations of monoclonal free light chains (FLCs) in the patients' sera.

Treatment strategies for patients with severe renal failure and multiple myeloma should first focus on correcting reversible factors such as dehydration and hypercalcaemia [7]. Second, disease specific treatments should be initiated rapidly and there is growing evidence for the role of new chemotherapeutic agents [810]. The third treatment option for these patients is direct removal of monoclonal FLCs from the serum. Historically, this has been undertaken using plasma exchange, however the efficacy of this treatment has never been established [1113].

Recently we described the removal of FLCs by extended haemodialysis, using the Gambro HCO 1100, as an alternative strategy [14]. Results of early pilot studies suggest that the procedure is not only effective at removing FLCs, but it is also associated with improved clinical outcome [6, 15]. In 17 patients with cast nephropathy treated, 12 recovered sufficient renal function to become independent of dialysis. This rate was a significantly higher than that of a case matched control population from the same institution, P < 0.01 [6].

The purpose of the EuLITE trial is to evaluate, in a controlled setting, FLC removal haemodialysis in patients with cast nephropathy, dialysis dependent renal failure and de novo multiple myeloma.

Methods/design

Hypothesis

The EuLITE trial examines the hypothesis that FLC removal haemodialysis will increase the rate of renal recovery in patients with cast nephropathy, severe renal failure and de novo multiple myeloma.

Design

The EuLITE trial is a prospective, randomised, multicentre, open label clinical trial to investigate the clinical benefit of FLC removal haemodialysis in patients with cast nephropathy, dialysis dependent renal failure and de novo multiple myeloma [16]. Inclusion and exclusion criteria are detailed in Table 1. At enrolment patients are randomised into one of two treatment groups (Figure 1):
Figure 1

Trial Schema.

Table 1

Inclusion and exclusion criteria

Inclusion criteria

    Age greater than 18 years

    Dialysis dependent acute renal failure (defined by: an estimated GFR of < 15 ml/min/1.73 m2)

    Fulfils criteria for the diagnosis of symptomatic de novo multiple myeloma

    Abnormal serum FLC ratio and a serum FLC concentration > 500 mg/L

    Myeloma kidney demonstrated on a renal biopsy (cast nephropathy)

    Commencement of study within 10 days of presenting to enrolling unit

Exclusion criteria

    Known advanced chronic renal failure (eGFR < 30 mls/min/1.73 m2) or evidence of significant chronic damage on renal biopsy

    Amyloidosis or light chain deposition disease on renal biopsy

    Previous treatment of multiple myeloma with chemotherapy

    Haemodynamic instability that precludes unsupported renal replacement therapy

    Significant cardiac disease

    Advanced disease or significant co-morbidity: with poor short term prognosis, necessitating palliation and no active or disease specific treatment.

    History of allergic reaction attributable to compounds containing boron or mannitol

    Peripheral neuropathy or neuropathic pain Grade 2 or higher

    Clinically significant liver dysfunction (bilirubin > 1.8 mg/dl (30 umol/L))

    Active uncontrolled infection or known HIV infection

    Inability to give informed consent

    Pregnant and lactating women

Group A (intervention): This group will receive extended haemodialysis using Gambro HCO 1100 dialysers and standard trial chemotherapy of: bortezomib, doxorubicin and dexamethasone.

Group B (control): This group will receive standard high flux haemodialysis (using a Gambro Polyflux-S dialyser) at intervals determined on clinical grounds by the nephrologist supervising care (minimum 4 hours 3 times per week) and standard trial chemotherapy of: bortezomib, doxorubicin and dexamethasone.

Randomisation is undertaken using random number generation by the programme Datinf RandGen (Datinf, Tubingen, Germany). The minimization algorithm described by Pockock and Simon [17] was employed to ensure balance between the intervention age groups (18–55, 56–65, 66–75 and 75+) and study centre. The allocation is made at random with a weighting in favour of the intervention that would minimize imbalance with a probability of 0.8. The seed for random number generation is stored securely to allow reproduction of the random numbers if required.

Study chemotherapy (both groups)

The first six patients entered into the study will comprise a cohort assessed for the safety of a reduced dose PAD regimen [18]. The modified regimen will consist of: bortezomib (1 mg/m2 on days 1, 4, 8 and 11 of a 21 day cycle); doxorubicin (9 mg/m2 on days 1 and 4 of the 21 day cycle) and dexamethasone (40 mg daily days 1–4, 8–11 and 15–18 for the first 21 day cycle and days 1–4 only on subsequent cycles). This safety assessment will be independent of the renal therapy to which they have been assigned.

Supportive therapy:

Co-trimoxazole 480 mg three times per week or alternative Pneumocystic carinii prophylaxis as per local institutional practice.

Ranitidine 150 mg twice daily whilst on dexamethasone

Metoclopramide 10–20 mg three times per day as required (20 mg to be given pre-chemo on day 1)

Allopurinol 100 mg orally daily

Aciclovir 200 mg twice per day, orally

Chemotherapy may have to be stopped or withheld for medical reasons. Such patients will be withdrawn from the treatment group and revert to standard care for their dialysis unit. Patients who withdraw for any reason will still be followed-up for all outcome measures, in order to enable an 'intention to treat analysis'.

FLC removal haemodialysis (group A only)

Participants will receive haemodialysis on non-bortezomib days: 6 hours on day 0, then 8 hours on days 2, 3, 5–7, 9+10. After day 12, participants will receive 8 hours of haemodialysis on alternate days. Dialysis will be undertaken using two Gambro HCO 1100 dialysers in series at a blood flow of 250 ml/min, dialysate flow of 500 ml/min, with adequate heparin (activated clotting time of 180–200 seconds). The supervising clinician will determine the fluid removal, with the aim to not dehydrate the patient.

Extended FLC removal haemodialysis will be supported by replacement of human albumin solution, in the last hour of each dialysis session (60 g). Magnesium, calcium and potassium will be replaced as required. After day 21, if patients still requires renal support the dialysis schedule will be reduced to 6 hours three times per week.

Primary endpoint

The primary endpoint of the study is independence of dialysis at three months from enrolment. Independence of dialysis will be defined as an estimated GFR of > 15 mls/min/1.73 m2, 2 weeks after the last dialysis session.

Patients' renal function will be assessed by biochemical markers (urea, creatinine and an estimated GFR) with monitoring of urine output. Patients who have a pre-dialysis eGFR of > 20 ml/min and a good urine out-put should receive a trial with out dialysis. The nephrologist responsible for the patients' care will decide when this is suitable. Patients who become independent of dialysis during the first 90 days, but subsequently require further dialysis support, so that they are dialysis dependent at the 3 month point will be classified as treatment failures.

Secondary endpoints

The first secondary endpoint is to determine the efficiency of FLC removal HD that results in sustained reductions in serum FLC concentrations versus a standard dialysis. Serum FLC concentrations will be measured pre- and post-dialysis, daily for the first 21 days on dialysis days.

It is proposed that patients with a cast nephropathy will recover their renal function more rapidly if their serum FLC concentrations are reduced quickly. We will, therefore, observe the duration of requirement for HD.

The management of patients with multiple myeloma is limited by renal impairment. It is conceivable that patients who recover renal function will have an increased chance of being suitable for high dose melphalan and stem cell transplantation, which is the current standard of care after primary chemotherapy. Response to treatment of multiple myeloma will be documented at the end of each chemotherapy cycle, then 6 and 12 months. Whether patients under 70 years of age have received a stem cell transplant will be recorded at 12 months.

Renal failure is the second commonest cause of death in patients with multiple myeloma. Therefore, patients who recover renal function should have a lower mortality rate. Overall survival will be recorded in both arms of the study.

Case report forms and data collection

All study data will be recorded on electronic Case Report Forms (eCRF) which are generated on a dedicated randomisation and remote data entry web server (Datinf, Tubingen, GmbH). The CRFs will be completed and signed by the local investigator or his/her designee as soon as the requested information is available. During the first 21 days, eCRFs will be completed for each dialysis day. These document the details of dialysis (including any breaches in protocol), biochemistry and haematological data. A specific eCRF is completed at the end of each chemotherapy cycle to document compliance with chemotherapy protocol. Time points for clinical and laboratory data are at the end of each cycle of chemotherapy and 3, 6, and 12 months.

Chemotherapy response

After a maximum of 4 cycles of treatment, patients will be assessed for response to PAD chemotherapy according to the International uniform response criteria for multiple myeloma [19]. If there is no evidence of response i.e. stable disease or progressive disease, then the patient will have been deemed to have failed PAD chemotherapy, and treatment will be switched to a regimen compatible with local institutional practice. Patients with a partial response or very good partial response will be eligible to continue for a maximum of 8 cycles. Patients who have achieved a stringent complete response or complete response will be eligible to stop chemotherapy and proceed to autologous peripheral blood stem cell collection if considered suitable for high dose therapy and stem cell rescue.

Statistical analysis plan

The primary analysis for the trial is to compare the experimental treatment with the control treatment in terms of independence of dialysis at three months. The proportion of patients independent of dialysis will be compared using point and interval estimates of relative risks and continuity-adjusted chi-square tests. The analysis will be carried out on an intention-to-treat basis. Due to the short follow-up required for the primary endpoint, missing data are not expected but the analysis will include these as failures and sensitivity analysis will assess the robustness of the conclusions to this assumption. As an additional analysis, time taken for independence of dialysis to occur will be compared between the two groups. Times will be censored for those patients who are not independent of dialysis at the time of analysis or lost to follow-up. Kaplan-Meier estimation and log-rank tests will be used to compare the groups.

The change in serum FLC concentrations over time will be compared across the two groups using longitudinal analysis with imputation used for any missing data. In particular, the treatment groups will be compared in terms of changes in mean pre-dialysis serum FLC concentrations for days 4–6, 8–10 and 20–22 relative to the pre-randomization level using analysis of variance. The appropriate parametric or non-parametric version of this analysis will be determined by graphical assessment of the normality of the data. Myeloma response at 6 and 12 months, and the proportion to have undergone a peripheral blood stem cell transplant at 12 months, will be compared across treatment groups using estimates of relative risks and continuity-adjusted chi-square tests. Mortality will be documented for a follow-up period of 24 months. Survival time will be censored for those patients still alive at the time of analysis or lost to follow-up and Kaplan-Meier estimation and log-rank tests will be used to compare treatment groups.

The balance of baseline factors across the two treatment groups will be assessed descriptively as hypothesis testing is not appropriate in this randomised setting. The key baseline factor in this setting is age which will be stratified for in the randomisation procedure. Analysis of the primary outcome measure will adjust for age using logistic regression modeling to ensure that the validity of the conclusions. Appropriate modeling will also be used to adjust for baseline factors in the analysis of any secondary outcomes.

Timing of analysis

Interim analysis will be carried out 3 months after the first 25 patients have been recruited and then when recruitment of 50% of target has been achieved. Data will be presented to an independent Data Monitoring Committee. The interim analysis will present recruitment data and data on outcomes and adverse events. Given the small size of the study, the interim analysis will be purely descriptive with the primary aim to assess patient safety and that it is ethical to continue. The study is expected to complete recruitment within 1 year. Final analysis will be carried out after all patients have been followed up for a minimum of 3 months and a further analysis of the survival outcome will be carried out after all patients have been followed-up for a minimum of 24 months.

Calculation of sample size

Sample size calculations are based on the primary outcome of independence of dialysis after 3 months from enrolment. Data from previous studies suggest a recovery rate of 25% in the control group and suggest that an improvement to 55% in the treatment group is a realistic expectation. Assuming an alpha error level of 5%, 41 patients are required in each treatment arm to detect this size of difference with 80% power. The primary analysis will be on an intention-to-treat basis but to enable sufficient power for any per-protocol analysis the final target is increased by 10% to allow for patients who withdraw from protocol treatment at the discretion of the treating physician. These patients will be followed-up for all outcome measures unless consent is withdrawn. The target recruitment is therefore 45 patients per arm, 90 patients in total.

Safety assessments

Safety assessments will include the monitoring and recording of all adverse events, including serious adverse events. Serious adverse events that are unexpected and considered by the investigator to be related to bortezomib will be reported to the ethics committee and the Medicines and Healthcare Products Regulatory Agency. Expected adverse events are presented in Table 2, unexpected are those not given. Grading and causality of the events will be undertaken by the site investigator and reviewed by the principal investigator.
Table 2

Expected adverse events

Dialysis related

Chemotherapy related

    Hypotension during dialysis

    Infections and infestations

    Dialysis line exit site infection

    Neoplasms benign, malignant and unspecified

    Cardiac arrhythmia

    Blood and lymphatic system disorders

    Septicaemia

    Immune system disorders

    Endocarditis

    Endocrine disorders

    Fluid overload

    Metabolism and nutrition disorders

    Peripheral oedema

    Psychiatric disorders

    Hypoalbuminemia

    Nervous system disorders

    Hypophosphatemia, hypomagnesemia, hypokalaemia, hypocalcaemia

    Eye disorders

    Hypersensitivity reactions

    Ear and labyrinth disorders

 

    Cardiac disorders (including cardiac tamponade)

 

    Vascular disorders

 

    Respiratory, thoracic and mediastinal disorders (including Pneumonitis, interstitial pneumonia, Acute Respiratory Distress Syndrome)

 

    Gastrointestinal disorders (including ischemic colitis and liver failure, hepatobiliary disorders)

 

    Skin and subcutaneous tissue disorders

 

    Musculoskeletal and connective tissue disorders

 

    Renal and urinary disorders

 

    Reproductive system and breast disorders

 

    Herpes meningoencephalitis

 

    Angioedema

 

    Encephalopathy, autonomic neuropathy

 

    Ophthalmic herpes

Summary

This trial will investigate the potential role of FLC removal haemodialysis in the management of patients with new multiple myeloma, cast nephropathy and dialysis dependent renal failure. If efficacious this therapy will offer clinicians new options in the management of these patients with historically very poor outcome.

Declarations

Acknowledgements

We are very grateful to all the clinicians who reviewed the protocol and advised the trial management group. We thank Gambro, Hechingen, Germany for providing the funding for this trial; The Binding Site, Birmingham, UK for supporting the laboratory analysis required and Ortho-biotech, High Wycombe, UK for provision of the study drug bortezomib.

Authors’ Affiliations

(1)
Department of Nephrology, University Hospital Birmingham
(2)
Division of Medical Sciences, University of Birmingham
(3)
Department of Haematology, University Hospital Birmingham
(4)
Department of Nephrology, University Hospital Tübingen
(5)
Department of Haematology, University Hospital Tübingen
(6)
Cancer Research UK Clinical Trials Unit, University of Birmingham
(7)
Division of Infection and Immunity, University of Birmingham

References

  1. Alexanian R, Barlogie B, Dixon D: Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med. 1990, 150: 1693-1695. 10.1001/archinte.150.8.1693.View ArticlePubMedGoogle Scholar
  2. Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S, Cases A, Darnell A, Rozman C, Montserrat E: Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998, 158: 1889-1893. 10.1001/archinte.158.17.1889.View ArticlePubMedGoogle Scholar
  3. Rayner HC, Haynes AP, Thompson JR, Russell N, Fletcher J: Perspectives in multiple myeloma: survival, prognostic factors and disease complications in a single centre between 1975 and 1988. Quart J Med. 1991, 79: 517-525.PubMedGoogle Scholar
  4. Sakhuja V, Jha V, Varma S, Joshi K, Gupta KL, Sud K, Kohli HS: Renal involvement in multiple myeloma: a 10-year study. Renal Failure. 2000, 22: 465-477. 10.1081/JDI-100100888.View ArticlePubMedGoogle Scholar
  5. Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV, Dispensenzieri A, Fervenza FC, Kumar S, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Hayman SR, Russel SJ, Kyle RA, Winters JL: Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int. 2008, 73 (11): 1282-8. 10.1038/ki.2008.108.View ArticlePubMedGoogle Scholar
  6. Hutchison CA, Basnayake K, Cook M, Bradwell AR, Cockwell P: Free Light Chain Hemodialysis Increases Renal Recovery Rate and Improves Patient Survival in Patients with Cast Nephropathy. Nephrol Dial Transplant Plus. 2008, 1 (Suppl 2): ii9a-Google Scholar
  7. Sanders PW: Pathogenesis and treatment of myeloma kidney. J Lab Clin Med. 1994, 124 (4): 484-8.PubMedGoogle Scholar
  8. Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S, Munshi NC, Schlossman R, Tariman J, Singhal S: Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood. 2007, 109 (6): 2604-6. 10.1182/blood-2006-09-046409.View ArticlePubMedGoogle Scholar
  9. Ludwig H, Drach J, Graf H, Lang A, Meran JG: Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica. 2007, 92 (10): 1411-1414. 10.3324/haematol.11463.View ArticlePubMedGoogle Scholar
  10. Kastritis E, Anagnostopoulos A, Roussou M, Gikka D, Matsouka C, Barmparousi D, Grapsa I, Psimenou E, Barmias A, Dimopoulos MA: Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimes and the impact of novel agents. Haematologica. 2007, 92: 546-549. 10.3324/haematol.10759.View ArticlePubMedGoogle Scholar
  11. Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM, Barrett BJ, Heidenheim AP, Garg AX, Churchill DN, Canadian Apheresis Group: Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med. 2005, 143 (11): 777-784.View ArticlePubMedGoogle Scholar
  12. Ritz E: Plasma exchange for acute renal failure of Myeloma – Logical, yet ineffective. J Am Soc Nephrol. 2006, 17: 914-916. 10.1681/ASN.2006080919.View ArticleGoogle Scholar
  13. Clark WF, Garg AX: Plasma exchange for myeloma kidney: cast (s) away?. Kidney Int. 2008, 73: 1211-1213. 10.1038/ki.2008.117.View ArticlePubMedGoogle Scholar
  14. Hutchison CA, Cockwell P, Reid S, Chandler K, Mead GP, Harrison J, Hattersley J, Evans ND, Chappel MJ, Cook M, Goehl H, Storr M, Bradwell AR: Efficient Removal of Immunoglobulin Free Light Chains by Hemodialysis for Multiple Myeloma: In-vitro and in-vivo studies. J Am Soc Nephrol. 2007, 18: 886-895. 10.1681/ASN.2006080821.View ArticlePubMedGoogle Scholar
  15. Bachmann U, Schindler R, Storr M, Kahl A, Joerres A, Sturm I: Combination of bortezomib-based cheometherapy and extracorpeal free light chain removal for treating cast nephropathy in multiple myeloma. Nephrol Dial Transplant Plus. 2008, 1: 106-108.Google Scholar
  16. International Myeloma Working Group: Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. British Journal of Haematology. 2003, 121: 749-757. 10.1046/j.1365-2141.2003.04355.x.View ArticleGoogle Scholar
  17. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trials. Biometrics. 1975, 31: 103-115. 10.2307/2529712.View ArticlePubMedGoogle Scholar
  18. Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, Agrawal S, Stec J, Schenkein D, Esseltine DL, Cavenagh JD: PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma). British J Haem. 2005, 129: 755-762. 10.1111/j.1365-2141.2005.05519.x.View ArticleGoogle Scholar
  19. Durie BG, Harousseau JL, Miguel JS: International uniform response criteria for multiple myeloma. Leukemia. 2006, 20: 1467-1473. 10.1038/sj.leu.2404284.View ArticlePubMedGoogle Scholar

Copyright

© Hutchison et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement